

TRIFAROTENE cream (Aklief® ▼) for treating acne vulgaris

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of TRIFAROTENE cream (Aklief® ▼) for treating acne vulgaris.

GREY

Trifarotene is indicated for the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present.^[1]

This recommendation will be reviewed if a formal application for use is received and prioritised for in-year review.

In the meantime, treatment of acne vulgaris should continue to follow national guidance, local pathways and local formulary choices:

- > NICE Guideline [NG198]: [Acne vulgaris: management](#) (25 June 2021)
- > NICE Clinical Knowledge Summaries: [Acne vulgaris](#) (June 2021)
- > Pan Mersey APC formulary: [Chapter 13.06: Acne and rosacea](#)

References

1. Galderma (U.K) Ltd. Summary of Product Characteristics; [Aklief 50 microgram/g cream](#), 18 December 2020. Accessed online 22 September 2022.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.